SEHK:1093
SEHK:1093Pharmaceuticals

How Investors Are Reacting To CSPC Pharmaceutical Group (SEHK:1093) Advancing New Hypertension and Diabetes Treatments

CSPC Pharmaceutical Group recently reported that its aldosterone synthase inhibitor SYH2072 secured U.S. FDA and China NMPA approvals to begin clinical trials for uncontrolled and resistant hypertension, while its fixed-dose Prusogliptin and Metformin Extended-Release diabetes therapy application was accepted by China’s NMPA. These parallel advances in hypertension and type 2 diabetes programs highlight CSPC’s push into higher-value, patent-protected treatments across major chronic disease...
SEHK:2171
SEHK:2171Biotechs

CARsgen Therapeutics Holdings SEHK 2171 Valuation After New Solid Tumor Collaboration With Dispatch Bio

Why this new collaboration matters for CARsgen Therapeutics Holdings (SEHK:2171) CARsgen Therapeutics Holdings (SEHK:2171) just announced a clinical collaboration with Dispatch Bio to run a Phase 1 trial in China, testing a combined approach for treating solid tumors using both companies' immunotherapies. The study, planned to begin in 2026, will evaluate DISP-11, which uses Dispatch's Flare platform and DV-10 tumor specific virus together with CARsgen's zevorcabtagene autoleucel, or zevor...
SEHK:3808
SEHK:3808Machinery

3 Asian Dividend Stocks To Consider With Up To 8.9% Yield

As Asia's markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on opportunities that provide stable returns amidst volatility. In this environment, dividend stocks stand out for their potential to deliver consistent income, making them an attractive option for those looking to balance growth prospects with reliable payouts.
SEHK:2252
SEHK:2252Medical Equipment

Asian Market Stocks That May Be Priced Below Intrinsic Value Estimates

As Asian markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on identifying stocks that may be priced below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and resilience to market fluctuations, making it an attractive option for those seeking potential opportunities in undervalued equities.
SEHK:512
SEHK:512Pharmaceuticals

Did TLX591-CDx NDA Acceptance and Nuclear Push Just Reframe Grand Pharmaceutical Group's (SEHK:512) Oncology Story?

Grand Pharmaceutical Group recently reported that China’s NMPA accepted its New Drug Application for TLX591-CDx (Illuccix®, gallium Ga 68 PSMA-11) for prostate cancer diagnosis, following positive Phase III data showing a 94.8% positive predictive value in Chinese patients with biochemically recurrent disease. Alongside this, the company outlined a broad push in nuclear medicine, with multiple Y-90 liver cancer indications cleared in the US and Europe and several radiopharmaceuticals...
SEHK:902
SEHK:902Renewable Energy

Did 2025’s 3.39% Sales Drop Just Shift Huaneng Power International's (SEHK:902) Investment Narrative?

Huaneng Power International, Inc. recently reported preliminary consolidated electricity sales for the fourth quarter and full year 2025, with power plants in the PRC selling 106.112 billion kWh in the quarter and 437.563 billion kWh for the year, both showing year-on-year declines. The annual sales decrease of 3.39% highlights a meaningful pullback in electricity demand or utilization across the company’s Chinese fleet, raising questions about underlying operating conditions. We will now...
SEHK:975
SEHK:975Metals and Mining

Mongolian Mining (SEHK:975) Is Up 13.4% After Stronger Coal Output And Portfolio Diversification Progress

Mongolian Mining Corporation released unaudited operational results for the quarter ended 31 December 2025, reporting higher run-of-mine coal output and increased washed coking coal production versus a year earlier. The company also reported full-year growth in washed coking coal sales volumes and continued to advance its copper-silver-gold project pipeline in Mongolia, underscoring a broader resource portfolio. We will now examine how higher washed coking coal sales and progress in...
SEHK:1
SEHK:1Industrials

Is CK Hutchison (SEHK:1) Pricing Reflect Its Strong Recent Share Price Performance?

This article examines whether CK Hutchison Holdings is attractively priced at its current level, or if the recent strength has already reflected much of its value, by breaking down what the numbers may indicate about the stock. With the share price at HK$61.35 and returns of 3.5% over 7 days, 12.6% over 30 days, 13.6% year to date, 60.9% over 1 year, 46.0% over 3 years, and 41.8% over 5 years, many investors are considering whether the current price is consistent with its...
SEHK:2269
SEHK:2269Life Sciences

Assessing WuXi Biologics (SEHK:2269) Valuation After New GMP Certifications And PatroLab Launch

WuXi Biologics (Cayman) (SEHK:2269) recently reported two compliance and technology milestones: fresh UK MHRA GMP certifications for key Wuxi plants and the launch of its PatroLabTM digital twin bioprocess platform. See our latest analysis for WuXi Biologics (Cayman). The latest compliance wins and PatroLabTM launch come as the share price sits at HK$38.4, with a 30-day share price return of 15.87% and a 1-year total shareholder return of 117.69%, while longer term three and five year total...
SEHK:6993
SEHK:6993Household Products

How Blue Moon’s Sharper Cost Focus And Detergent Push At Blue Moon Group Holdings (SEHK:6993) Has Changed Its Investment Story

In January 2026, Blue Moon Group Holdings Limited announced earnings guidance indicating it expects at least a 50% reduction in its loss attributable to equity holders for 2025 compared with the approximately HK$749.30 million loss recorded for 2024. The company attributes this anticipated improvement to tighter cost optimisation, streamlined operations and continued investment in new product promotion and channel expansion, particularly for concentrated liquid laundry detergents. Next, we...